FY2017 Earnings Estimate for Lipocine Inc. Issued By Zacks Investment Research (LPCN)
Lipocine Inc. (NASDAQ:LPCN) – Equities researchers at Zacks Investment Research upped their FY2017 EPS estimates for Lipocine in a research note issued to investors on Tuesday. Zacks Investment Research analyst J. Vandermosten now forecasts that the specialty pharmaceutical company will earn ($1.16) per share for the year, up from their prior estimate of ($1.17).
Lipocine (NASDAQ:LPCN) last released its earnings results on Monday, August 7th. The specialty pharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. TRADEMARK VIOLATION NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/fy2017-earnings-estimate-for-lipocine-inc-issued-by-zacks-investment-research-lpcn/1467745.html.
Several other analysts have also recently commented on the company. Roth Capital set a $38.00 price target on Lipocine and gave the stock a “buy” rating in a research report on Tuesday, June 20th. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Lipocine in a research report on Wednesday, April 26th. Canaccord Genuity set a $10.00 price target on Lipocine and gave the stock a “buy” rating in a research report on Monday, April 24th. Finally, ValuEngine cut Lipocine from a “hold” rating to a “sell” rating in a research report on Thursday.
Shares of Lipocine (NASDAQ:LPCN) opened at 4.32 on Thursday. The stock’s market capitalization is $83.21 million. Lipocine has a 12-month low of $3.03 and a 12-month high of $5.90. The company has a 50-day moving average of $4.45 and a 200 day moving average of $3.99.
A number of hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp boosted its stake in shares of Lipocine by 7.1% in the first quarter. Bank of New York Mellon Corp now owns 92,979 shares of the specialty pharmaceutical company’s stock valued at $362,000 after buying an additional 6,191 shares during the last quarter. KCG Holdings Inc. boosted its stake in shares of Lipocine by 27.4% in the first quarter. KCG Holdings Inc. now owns 33,537 shares of the specialty pharmaceutical company’s stock valued at $131,000 after buying an additional 7,219 shares during the last quarter. Federated Investors Inc. PA boosted its stake in shares of Lipocine by 9.2% in the second quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock valued at $354,000 after buying an additional 7,429 shares during the last quarter. Parametric Portfolio Associates LLC boosted its stake in shares of Lipocine by 27.1% in the first quarter. Parametric Portfolio Associates LLC now owns 58,739 shares of the specialty pharmaceutical company’s stock valued at $229,000 after buying an additional 12,518 shares during the last quarter. Finally, LMR Partners LLP bought a new stake in shares of Lipocine during the second quarter valued at about $173,000. Institutional investors own 38.88% of the company’s stock.
Lipocine Company Profile
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.